Radiopharm Theranostics (ASX:RAD) completed the dosing of the final patient in the US phase 2b imaging trial evaluating the diagnostic performance of fluorine-18-RAD101 in 30 individuals with confirmed recurrent brain metastases from solid tumors of different origins, according to a Thursday Australian bourse filing.

The primary objective of the study is concordance between fluorine-18-RAD101 positive lesions and those seen in conventional imaging, magnetic resonance imaging with gadolinium, in participants with suspected recurrent brain metastases.

RAD 101 is a novel imaging small molecule that targets fatty acid synthase (FASN), a multi-enzyme protein that catalyses fatty acid synthesis and is overexpressed in many solid tumors.